US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

6.36

-0.1100-1.70%

Post-market: 6.360.00000.00%19:30 EDT

Volume:58.07K

Turnover:373.25K

Market Cap:709.20M

PE:-33.42

High:6.67

Open:6.41

Low:6.34

Close:6.47

52wk High:9.42

52wk Low:5.44

Shares:111.51M

Float Shares:35.93M

Volume Ratio:1.43

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1903

EPS(LYR):0.0225

ROE:-17.44%

ROA:-5.42%

PB:6.57

PE(LYR):282.87

Loading ...

Overview Company News Filings

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Sight Sciences (SGHT) and Gyre Therapeutics (GYRE)

Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate

Benzinga Earnings

Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates

Earnings Flash (GYRE) Gyre Therapeutics Posts Q1 Loss $0.10 a Share, vs. FactSet Est of $0.07 Loss

MT Newswires Live

Gyre Therapeutics Q1 Net Income USD -9.858 Million

THOMSON REUTERS

Gyre Therapeutics Inc - Affirms FY2026 Revenue Guidance of $100.5 Mln-$111.0 Mln

THOMSON REUTERS

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Gyre Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

BRIEF-Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical Company

Gyre Therapeutics completes $300 million acquisition of Cullgen

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-Based Fully Integrated Biopharmaceutical Company

THOMSON REUTERS

US High Growth Tech Stocks To Watch

Simply Wall St.

Gyre Therapeutics amends 8-K to correct Cullgen merger share conversion description

Gyre Therapeutics announces annual shareholder meeting

Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis

Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/GYRE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":6.36,"timestamp":1788379200000,"preClose":6.47,"halted":0,"volume":58066,"hourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.36,"latestTime":"19:30 EDT","volume":523,"amount":3326.13,"timestamp":1788391806313,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01700154559505401,"floatShares":35934500,"shares":111509800,"eps":-0.190324,"marketStatus":"Not Yet Opened","change":-0.11,"latestTime":"09-02 16:00:00 EDT","open":6.41,"high":6.67,"low":6.3372,"amount":373253.561039,"amplitude":0.051437,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.190324,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":6.47,"preHourTrading":{"tag":"盘前","latestPrice":6.47,"preClose":6.47,"latestTime":"09:25 EDT","volume":4,"amount":25.88,"timestamp":1788355532163,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.36,"latestTime":"19:30 EDT","volume":523,"amount":3326.13,"timestamp":1788391806313,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.426073,"impliedVol":1.7029,"impliedVolPercentile":0.8611},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":35934500,"roa":"-5.42%","roe":"-17.44%","lyrEps":0.022484,"volumeRatio":1.426073,"shares":111509800,"dividePrice":0,"high":6.67,"amplitude":0.051437,"preClose":6.47,"low":6.3372,"week52Low":5.44,"pbRate":"6.57","psRate":"6.46","week52High":9.42,"institutionHeld":0.2764,"latestPrice":6.36,"eps":-0.190324,"divideRate":0,"volume":58066,"delay":0,"ttmEps":-0.190324,"open":6.41,"prevYearClose":7.06,"prevWeekClose":6.59,"prevMonthClose":6.57,"prevQuarterClose":6.59,"fiveDayClose":6.65,"twentyDayClose":6.23,"sixtyDayClose":6.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"GYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2026-05-07","symbol":"GYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2026-03-12","symbol":"GYRE","fiscalQuarterEnding":"2025/12","expectedEps":0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":0.04},{"market":"US","date":"2025-11-07","symbol":"GYRE","fiscalQuarterEnding":"2025/09","expectedEps":0.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.05},{"market":"US","date":"2025-08-11","symbol":"GYRE","fiscalQuarterEnding":"2025/06","expectedEps":0.03,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1760155200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2026-09-01","current":-33.4167,"percent":0.195578,"low":-11548.718266,"twenty":-32.602728,"median":-9.652614,"eighty":115.68348,"high":193.429414,"avg":-540.923701,"sd":2271.881648,"marketCap":696641822},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678},{"date":"2025-07-03","current":101.646411,"twenty":-26.790554,"median":-11.75017,"eighty":66.71,"marketCap":737038125},{"date":"2025-07-11","current":97.645568,"twenty":-23.367997,"median":-11.701017,"eighty":68.524795,"marketCap":708028014},{"date":"2025-07-18","current":92.394462,"twenty":-17.913275,"median":-11.686523,"eighty":70.505622,"marketCap":669952244},{"date":"2025-07-25","current":92.269436,"twenty":-17.24169,"median":-11.594732,"eighty":71.634434,"marketCap":669045678},{"date":"2025-08-01","current":88.143567,"twenty":-16.863516,"median":-11.531927,"eighty":73.525921,"marketCap":639129001},{"date":"2025-08-08","current":90.018962,"twenty":-16.53533,"median":-11.498109,"eighty":77.782591,"marketCap":652727491},{"date":"2025-08-15","current":179.246974,"twenty":-16.326683,"median":-11.42614,"eighty":87.268382,"marketCap":746563646},{"date":"2025-08-22","current":164.643977,"twenty":-16.268001,"median":-11.353175,"eighty":89.218793,"marketCap":685742166},{"date":"2025-08-29","current":180.563196,"twenty":-16.183906,"median":-11.256552,"eighty":90.29402,"marketCap":752045713},{"date":"2025-09-05","current":165.298192,"twenty":-16.049822,"median":-11.217903,"eighty":91.769331,"marketCap":688466969},{"date":"2025-09-12","current":177.074053,"twenty":-16.011538,"median":-11.179254,"eighty":92.594504,"marketCap":737513429},{"date":"2025-09-19","current":167.696978,"twenty":-15.943032,"median":-11.12128,"eighty":93.569709,"marketCap":698457915},{"date":"2025-09-26","current":158.974119,"twenty":-15.763593,"median":-11.111618,"eighty":95.145041,"marketCap":662127204},{"date":"2025-10-03","current":163.989763,"twenty":-15.70726,"median":-11.048813,"eighty":96.920416,"marketCap":683017363},{"date":"2025-10-10","current":155.921118,"twenty":-15.633582,"median":-10.966684,"eighty":99.846032,"marketCap":649411455},{"date":"2025-10-17","current":190.594485,"twenty":-15.61523,"median":-10.876478,"eighty":100.896253,"marketCap":793826030},{"date":"2025-10-24","current":179.472839,"twenty":-15.600803,"median":-10.763776,"eighty":101.646411,"marketCap":747504374},{"date":"2025-10-31","current":166.824692,"twenty":-15.546428,"median":-10.691308,"eighty":105.447211,"marketCap":694824844},{"date":"2025-11-07","current":160.064476,"twenty":-15.429294,"median":-10.618842,"eighty":111.643728,"marketCap":666668543},{"date":"2025-11-14","current":110.418625,"twenty":-15.377823,"median":-10.570531,"eighty":112.102687,"marketCap":734394278},{"date":"2025-11-21","current":102.355879,"twenty":-15.373231,"median":-10.435259,"eighty":110.254637,"marketCap":680768953},{"date":"2025-11-28","current":105.908954,"twenty":-15.35855,"median":-10.377285,"eighty":109.598685,"marketCap":704400452},{"date":"2025-12-05","current":107.958805,"twenty":-15.300832,"median":-10.338636,"eighty":109.462028,"marketCap":718034009},{"date":"2025-12-12","current":107.548834,"twenty":-15.279098,"median":-10.299987,"eighty":109.871999,"marketCap":715307298},{"date":"2025-12-19","current":100.442685,"twenty":-15.279098,"median":-10.179208,"eighty":109.598685,"marketCap":668044300},{"date":"2025-12-26","current":98.256178,"twenty":-15.261711,"median":-10.046352,"eighty":109.489359,"marketCap":653501839},{"date":"2026-01-02","current":96.479641,"twenty":-15.250843,"median":-9.954769,"eighty":109.29804,"marketCap":641686089},{"date":"2026-01-09","current":103.449133,"twenty":-15.243518,"median":-9.652614,"eighty":109.106721,"marketCap":688040184},{"date":"2026-01-16","current":105.22567,"twenty":-15.23799,"median":-9.652614,"eighty":108.560094,"marketCap":699855933},{"date":"2026-01-23","current":110.008655,"twenty":-15.222589,"median":-9.517342,"eighty":109.134052,"marketCap":731667567},{"date":"2026-01-30","current":112.195163,"twenty":-15.163907,"median":-9.314435,"eighty":109.544022,"marketCap":746210028},{"date":"2026-02-06","current":102.629193,"twenty":-15.092184,"median":51.163441,"eighty":109.680679,"marketCap":682586761},{"date":"2026-02-13","current":106.865551,"twenty":-15.037849,"median":54.920332,"eighty":109.544022,"marketCap":710762779},{"date":"2026-02-20","current":115.064954,"twenty":-14.972646,"median":56.469566,"eighty":109.844668,"marketCap":765297008},{"date":"2026-02-27","current":116.431521,"twenty":-14.918384,"median":59.41311,"eighty":110.555282,"marketCap":774386046},{"date":"2026-03-06","current":107.002208,"twenty":-14.903389,"median":60.420111,"eighty":111.484548,"marketCap":711671683},{"date":"2026-03-13","current":141.117848,"twenty":-14.871908,"median":65.067812,"eighty":112.058506,"marketCap":709399423},{"date":"2026-03-20","current":123.520041,"twenty":-14.817461,"median":66.926893,"eighty":112.457994,"marketCap":620935247},{"date":"2026-03-27","current":127.879572,"twenty":-14.672715,"median":68.213723,"eighty":113.15176,"marketCap":642850609},{"date":"2026-04-02","current":131.330867,"twenty":-14.637941,"median":68.717439,"eighty":113.9717,"marketCap":660200270},{"date":"2026-04-10","current":131.512514,"twenty":-14.560386,"median":70.412668,"eighty":115.791328,"marketCap":661113410},{"date":"2026-04-17","current":143.501224,"twenty":-14.518403,"median":70.916169,"eighty":118.208058,"marketCap":721380655},{"date":"2026-04-24","current":135.145457,"twenty":-14.464068,"median":71.829251,"eighty":123.520041,"marketCap":679376212},{"date":"2026-05-01","current":139.504988,"twenty":-14.451664,"median":72.980471,"eighty":126.240493,"marketCap":701291573},{"date":"2026-05-08","current":-107.788052,"twenty":-14.451664,"median":73.535777,"eighty":127.334631,"marketCap":685747587},{"date":"2026-05-15","current":-100.534989,"twenty":-14.637941,"median":72.372236,"eighty":126.808829,"marketCap":639603601},{"date":"2026-05-22","current":-88.758033,"twenty":-14.909982,"median":71.342209,"eighty":126.608042,"marketCap":564678607},{"date":"2026-05-29","current":-82.438691,"twenty":-15.079143,"median":70.645053,"eighty":126.314003,"marketCap":524474952},{"date":"2026-06-05","current":-88.901655,"twenty":-15.242525,"median":70.38405,"eighty":126.098579,"marketCap":565592327},{"date":"2026-06-12","current":-87.034576,"twenty":-15.283445,"median":68.648906,"eighty":126.010611,"marketCap":553713974},{"date":"2026-06-18","current":-87.321819,"twenty":-15.377362,"median":68.088818,"eighty":124.946974,"marketCap":555541413},{"date":"2026-06-26","current":-89.47614,"twenty":-15.611553,"median":66.655777,"eighty":123.810677,"marketCap":569247204},{"date":"2026-07-02","current":-93.641161,"twenty":-15.753857,"median":65.067812,"eighty":123.374723,"marketCap":595745068},{"date":"2026-07-10","current":-120.215892,"twenty":-16.183906,"median":60.420111,"eighty":122.720794,"marketCap":764813504},{"date":"2026-07-17","current":-112.505251,"twenty":-16.863516,"median":59.41311,"eighty":121.124631,"marketCap":715758410},{"date":"2026-07-24","current":-105.320337,"twenty":-26.790554,"median":56.469566,"eighty":119.109992,"marketCap":670047982},{"date":"2026-07-31","current":-101.8155,"twenty":-28.630129,"median":54.920332,"eighty":118.134453,"marketCap":647750212},{"date":"2026-08-07","current":-112.154768,"twenty":-30.09916,"median":51.163441,"eighty":117.790204,"marketCap":713528633},{"date":"2026-08-14","current":-32.674966,"twenty":-30.809057,"median":-9.314435,"eighty":117.359023,"marketCap":693460810},{"date":"2026-08-21","current":-35.073129,"twenty":-31.698577,"median":-9.517342,"eighty":116.303482,"marketCap":744357016},{"date":"2026-08-28","current":-33.37443,"twenty":-32.401491,"median":-9.652614,"eighty":115.755379,"marketCap":708305536},{"date":"2026-09-01","current":-32.824851,"twenty":-32.602728,"median":-9.652614,"eighty":115.68348,"marketCap":696641822}],"updateTime":1788413797519},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635324053","title":"Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2635324053","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635324053?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May  12, 2026  (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with oper","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293396/0/en/Gyre-Therapeutics-Announces-NMPA-Acceptance-of-New-Drug-Application-for-F351-hydronidone-for-CHB-Induced-Liver-Fibrosis-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223082519.USD","BK4006","LU1223083913.SGD","BK4017","BK4139","CHB","GYRE","HCC","IND","LU1223082196.USD","CDE","BK4021","DAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633451709","title":"Noble Financial Sticks to Their Buy Rating for Gyre Therapeutics (GYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633451709","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633451709?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:12","pubTimestamp":1778245967,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics, with a price target of $20.00. LeBoye...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-their-buy-rating-for-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBL","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633712241","title":"Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2633712241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633712241?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:59","pubTimestamp":1778173170,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $22.52M, consensus $31.61M. “Building on our successful pre-NDA meeting with China’s CDE at the beginning of the year, we are pa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-reports-q1-eps-10c-vs-0c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-reports-q1-eps-10c-vs-0c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633281951","title":"Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633281951","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633281951?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:32","pubTimestamp":1778160741,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryGyre Therapeutics Inc GYRE.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended March","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K1PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314039","title":"Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Sight Sciences (SGHT) and Gyre Therapeutics (GYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314039?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:01","pubTimestamp":1778158881,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Siemens Healthineers AG (SEMHF), Sight Sciences (SGH...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-siemens-healthineers-ag-othersemhf-sight-sciences-sght-and-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-siemens-healthineers-ag-othersemhf-sight-sciences-sght-and-gyre-therapeutics-gyre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LU0128526141.USD","GYRE","LU0029874061.USD","BK4082","BK4539","XBI","BK4588","LABU","BK4210","BK4585","SEMHF","HCSG","BK4137","BK4581","BK4139","AG","SGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633170321","title":"Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633170321","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633170321?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:21","pubTimestamp":1778149282,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent.  The company reported quarterly sales of $22.519 million which missed","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52357560/gyre-therapeutics-q1-adj-eps-0-04-beats-0-07-estimate-sales-22-519m-miss-31-607m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117232","title":"Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117232","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117232?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:16","pubTimestamp":1778149016,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimatesOverviewUS biopharmaceutical firm's Q1 revenue rose 2% yr/yr, missing analyst expectationsCompany posted a net loss as operating expen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K0GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117880","title":"Earnings Flash (GYRE) Gyre Therapeutics Posts Q1 Loss $0.10 a Share, vs. FactSet Est of $0.07 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117880","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117880?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:05","pubTimestamp":1778148303,"startTime":"0","endTime":"0","summary":"Earnings Flash (GYRE) Gyre Therapeutics Posts Q1 Loss $0.10 a Share, vs. FactSet Est of $0.07 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633611260","title":"Gyre Therapeutics Q1 Net Income USD -9.858 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633611260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633611260?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXF6AA7E:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117863","title":"Gyre Therapeutics Inc - Affirms FY2026 Revenue Guidance of $100.5 Mln-$111.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117863?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXF6AA7E:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117543","title":"Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117543","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117543?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148000,"startTime":"0","endTime":"0","summary":"Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289709/0/en/Gyre-Therapeutics-Reports-First-Quarter-2026-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","BK4139","DAC","LU1223082519.USD","BK4017","BK4021","LU1223083913.SGD","BK4023","LU1169590202.USD","CHB","LU1223082196.USD","LU1169589451.USD","PD","IND","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633173943","title":"Gyre Therapeutics Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633173943","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633173943?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:58","pubTimestamp":1777985886,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc  expected to post a loss of7cents a share - Earnings Preview Gyre Therapeutics Inc GYRE.OQ GYRE.O is expected to  show a rise in quarterly revenue when it reports  results on May","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1O7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632052953","title":"BRIEF-Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2632052953","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632052953?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:49","pubTimestamp":1777898949,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical CompanyMay 4 (Reuters) - Gyre Therapeutics Inc GYRE.O:GYRE THERAPEUTICS COMP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3HTXHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632035953","title":"Gyre Therapeutics completes $300 million acquisition of Cullgen","url":"https://stock-news.laohu8.com/highlight/detail?id=2632035953","media":"Reuters","labels":["executive","corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632035953?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:48","pubTimestamp":1777898887,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics completed acquisition of privately held Cullgen in an all-stock transaction valued at about USD 300 million, creating a U.S.- and China-based biopharmaceutical company.Cullgen became a wholly owned subsidiary; former Cullgen CEO Ying Luo was appointed Gyre president and CEO, joining board, while Ping Zhang remains chairman.Combined group retains Nasdaq listing under ticker GYRE, adding Cullgen targeted protein degrader and degrader-antibody conjugate platform to Gyre fibrosis and inflammatory disease portfolio.Portfolio includes China-marketed lung fibrosis drug ETUARY, lead liver fibrosis candidate F351  with an NDA under priority review in China, ETUARY Phase 3 trial enrollment completed in pneumoconiosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL8n2Tzb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","GYRE","LU2095319765.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","BK4585","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014013.SGD","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632530349","title":"Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-Based Fully Integrated Biopharmaceutical Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2632530349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632530349?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:47","pubTimestamp":1777898867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA3HTXHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630197563","title":"US High Growth Tech Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2630197563","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630197563?lang=en_us&edition=fundamental","pubTime":"2026-04-28 01:08","pubTimestamp":1777309706,"startTime":"0","endTime":"0","summary":"The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gyre/gyre-therapeutics/news/us-high-growth-tech-stocks-to-watch-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gyre/gyre-therapeutics/news/us-high-growth-tech-stocks-to-watch-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","GYRE","SVRA","BK4023","BK4613","KVYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628121209","title":"Gyre Therapeutics amends 8-K to correct Cullgen merger share conversion description","url":"https://stock-news.laohu8.com/highlight/detail?id=2628121209","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628121209?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:56","pubTimestamp":1776430570,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics filed an amended Form 8-K to correct a clerical error in its March 2, 2026 report describing how certain non-designated Cullgen stockholders’ shares convert in proposed merger.Revised disclosure clarifies that designated Cullgen holders receive Series B Convertible Preferred Stock, while other holders receive Gyre common stock, using exchange ratio 0.4753.Gyre reiterated that Series B Convertible Preferred Stock converts into five shares of common stock, subject to conditions tied to stockholder approval of Conversion Proposal.Amendment kept valuation of all-stock deal unchanged at about $300 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL5nvxYY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628249867","title":"Gyre Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628249867","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628249867?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:14","pubTimestamp":1776370483,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics schedules 2026 annual stockholder meeting for June 10, 2026 in virtual format.Shareholders will vote on election of two Class II directors to serve through 2029.Ballot includes advisory vote on named executive officer compensation.Items also include ratification of Grant Thornton Zhitong Certified Public Accountants as independent auditor for 2026.Another proposal seeks approval for issuance of common shares upon conversion of Series B Convertible Preferred Stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL4qCwVj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089227","title":"Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089227","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621089227?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:51","pubTimestamp":1774266708,"startTime":"0","endTime":"0","summary":"Gyre said its majority indirectly owned subsidiary Gyre Pharmaceuticals submitted a New Drug Application to China’s National Medical Products Administration’s Center for Drug Evaluation for F351 .The filing seeks approval to treat chronic hepatitis B-induced liver fibrosis and is subject to initial formatting and completeness verification.The regulator is expected to issue an acceptance number before starting its technical review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9BBm98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620047534","title":"Buy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2620047534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620047534?lang=en_us&edition=fundamental","pubTime":"2026-03-17 22:15","pubTimestamp":1773756916,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Gyre Therapeutics, with a price target of $18.00. Matthe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-gyre-therapeutics-driven-by-priority-review-of-hydronidone-in-china-and-de-risked-path-to-2026-conditional-approval-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-gyre-therapeutics-driven-by-priority-review-of-hydronidone-in-china-and-de-risked-path-to-2026-conditional-approval-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":77,"code":"91000000","status":"200"}]}}